An open-label, randomised, Best-Available-Care (BAC) and historic-controlled trial of
nebulised dornase alfa [2.5 mg BID] for 7 days in participants with COVID-19 who are admitted
to hospital and are at risk of ventilatory failure (the COVASE study). Controls will include
a randomised arm to receive BAC, historic data from UCLH patients with COVID-19 and biobanked
samples will be used to demonstrate an effect of dornase alfa. CRP will be measured to assess
the effect of dornase alfa on inflammation. Clinical endpoints and biomarkers (e.g. d-dimer)
will be used to assess the clinical response. Exploratory endpoints will explore the effects
of dornase alfa on features of neutrophil extracellular traps (NETs).